Clinical trials: Colorectal Cancer Liver Metastases (CRLM)
Hepatocellular Carcinoma, Hepatocellular Cancer
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer, Colorectal Carcinoma
- Trial name
- NCT04912765
- Testing
- Neoantigen Dendritic Cell Vaccine, Nivolumab
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- National Cancer Centre, Singapore
Colorectal Neoplasms
Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
The PUMP-IT study is designed to prove the feasibility of HAIP chemotherapy with concomitant standard systemic chemotherapy (FOLFOX and FOLFIRI) in the Netherlands.
- Trial name
- PUMP-IT (NCT04552093)
- Testing
- Floxuridine, Tricumed IP2000V infusion pump
- Where
- Netherlands
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- The Netherlands Cancer Institute
Colorectal Cancer, Liver Metastases
The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients
establishment and validation of the prediction model of avastin plus chemotherapy as first line treatment in simultaneous ras mutant unresectable CRLM patients
- Trial name
- NCT04525313
- Volunteers
- 116 people
- Sponsor
- Fudan University
Colorectal Cancer Liver Metastases (CRLM)
AI-Based Prediction of Liver Metastasis in Colorectal Cancer (A Retrospective Study)
This multicenter, retrospective study aims to develop and validate a multimodal deep learning model for predicting the risk of metachronous liver metastasis in patients with stage I-III colorectal cancer following curative…
- Trial name
- NCT07399236
- Testing
- Multimodal Deep Learning Model Analysis
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Tongji Hospital
Colorectal Cancer Liver Metastasis
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM
- Trial name
- NCT06788171
- Testing
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy, Bevacizumab, Capecitabine
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Colon Cancer Liver Metastasis, Contrast Enhances Intraoperative Ultrasound
Detection Rate of Liver Metastases With Contrast Enhanced Intraoperative Ultrasound Compared to Regular Imaging
The study compares the established imaging techniques (CT, MRT, Contrast Ultrasound) with the new method of intraoperative contrast enhanced ultrasound to compare all methods for their rate of detection of colorectal liver…
- Conditions
- Colon Cancer Liver Metastasis, Contrast Enhances Intraoperative Ultrasound, Imaging for Liver Cancer, Imaging for Liver Metastasis
- Trial name
- CEIOUS-Liver (NCT01522209)
- Testing
- Liver Surgery, Contrast Enhanced Ultrasound, CT Scan (standard)
- Where
- Germany
- Volunteers
- 59 people
- Sponsor
- Asklepios Kliniken Hamburg GmbH
Colorectal Liver Metastases
Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases
Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts.
- Trial name
- COLDFIRE-2 (NCT02082782)
- Testing
- Irreversible electroporation (IRE)
- Where
- 3 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- Amsterdam UMC, location VUmc
Colorectal Neoplasms Malignant
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
The goal of this clinical trial is to investigate the effectiveness of localized interventions in improving the 5-year survival rate for colorectal cancer patients with ≥10 liver metastases.
- Trial name
- NCT06208371
- Testing
- Surgical resection and/or ablation therapy and/or SBRT, Palliative Chemotherapy
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Sun Yat-sen University
Colorectal Adenocarcinoma Metastatic to the Liver
Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
To date no prospective trials have been completed that demonstrated whether HAI is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in conversional resection rates and survival compared…
- Trial name
- NCT03125161
- Testing
- HAI, chemotherapy ± target therapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fudan University
Colorectal Cancer Metastatic
Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM
Retrospective evaluation of the efficacy and safety of DEB-TACE combined with HAIC versus HAIC alone in patients with unresectable colorectal liver metastases (CRLM)
- Trial name
- NCT07031570
- Volunteers
- 500 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Cancer Metastatic
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
This prospective, randomized, controlled clinical study aims to evaluate the objective remission rate of FOLFOX hepatic artery infusion chemotherapy (HAI) in combination with systemic irinotecan with or without bevacizumab versus…
- Trial name
- NCT05727163
- Testing
- Dexamethasone, Anisodamine, Oxaliplatin
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer (CRC), Colorectal Cancer Liver Metastases (CRLM)
MRD-Guided Surveillance in Resectable Stage IV Metastatic Colorectal Cancer (SURVEILLANCE-II)
This study aims to explore the relationship between minimal residual disease (MRD) status and disease recurrence in patients with resectable stage IV metastatic colorectal cancer (mCRC).
- Trial name
- SURII (NCT06879886)
- Volunteers
- 181 people
- Sponsor
- Fudan University
Colorectal Cancer, Liver Metastases
Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM
The primary objectives of this phase I/II, prospective clinical trial, are to assess the optimal dose, efficacy, safety and immunological effect of ablation and intra-tumoral injection of a novel immuno-adjuvant (IP-001) for…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer
- Trial name
- INJECTABL-II (NCT06630624)
- Testing
- IP-001
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- M.R. Meijerink
CRC, Liver Metastasis Colon Cancer
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM
This prospective study aims to investigate the efficacy and safety of peritumoral injection of the oncolytic virus H101 in combination with stereotactic body radiotherapy (SBRT), PD-1 monoclonal antibody, chemotherapy, and…
- Trial name
- VVSHIP (NCT07381309)
- Testing
- SBRT, PD-1 Antibody, H101
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Jun Huang
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
This phase IIb trial tests the effect of HRX215 in treating patients with colorectal cancer that has spread from where it first started to the liver (liver metastasis) after undergoing a portal vein embolization (PVE).
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07612007
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR)
The DRAGON 2 Trial
In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE/HVE (interventional group).
- Trial name
- DRAGON 2 (NCT05428735)
- Testing
- Embolization
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 348 people
- Sponsor
- Maastricht University
Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
This single-arm phase II trial enrolls patients with RAS-mutant, microsatellite-stable (MSS) unresectable colorectal cancer liver metastases receiving first-line treatment with Retlirafusp alfa combined with XELOX (capecitabine…
- Trial name
- NCT07797244
- Testing
- Retlirafusp alfa+XELOX+Bevacizumab Treatment
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Dai, Guanghai
Colorectal Cancer Metastatic
Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM
To observe the PFS of yttrium [90Y] microsphere injection combined with FOLFIRI and bevacizumab in second-line treatment of CRLM.
- Trial name
- NCT06447727
- Testing
- SIRT with Yttrium-90 Microspheres, FOLFIRI and Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhongda Hospital
Colorectal Cancer, Liver Metastases
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
For patients with initially resectable colorectal cancer liver metastases who have high-risk factors, neoadjuvant therapy is currently considered a consensus approach.
- Trial name
- NCT05948072
- Testing
- mFOLFOX6 + Cetuximab, mFOLFOX 6
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer
Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases
This is a prospective, single-center, single-arm exploratory clinical study designed to evaluate the efficacy and safety of hepatic arterial infusion of liposomal irinotecan combined with systemic oxaliplatin and capecitabine as…
- Conditions
- Colorectal Cancer Liver Metastases (CRLM), Colorectal Cancer, Liver Metastasis
- Trial name
- NCT07570914
- Testing
- Liposomal Irinotecan, Oxaliplatin, Capecitabine
- Volunteers
- 28 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital